The history of CML has changed dramatically thanks to the introduction in the 1990’s of tyrosine kinase inhibitors, which are drugs capable of blocking the constitutive activation of BCR–ABL1. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.